Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-126

Why would these comments come out if this was not a positive announcement?

Director of Dermatology, Clinical studies and Division Head of Dermatology at Henry Ford Health System in Michigan USA, Dr Linda Stein Gold commented: “The safety and efficacy outcomes provide confidence that synthetic cannabidiol can represent an exciting new treatment option for acne patients. “The effect on comedones (inflammatory lesions) is particularly pleasing, given BTX 1503’s proposed mechanisms on the underlying causes of acne including inflammation and bacterial infection.”


Australian investigator and Fellow of the Australasian College of Dermatologists, Dr Catherine Reid: “Patients found PermetrexTM enabled BTX 1503 easy to apply, it was not sticky and didn’t burn or sting.” “We are pleased to have contributed to this study and are excited by the potential of BTX 1503 and we look forward to participating in the Phase 3 study program.”